SC
KPTI icon

Shay Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Shay Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,417
Closed -$95.1K – 384
2025
Q1 		$95.1K Buy
25,417
+13,940
+121% +$119K 0.01% 275
2024
Q4 		$116K Buy
+11,477
New +$139K 0.02% 273

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Shay Capital's KPTI Position: Q2 2025 in Review

Shay Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 25,417 shares — an estimated $95.1K sold.

Shay Capital first reported a position in KPTI in Q4 2024 and held it in 2 quarters. The position peaked at $116K in Q4 2024. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

  • Shay Capital reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 25,417 Karyopharm Therapeutics shares in Q2 2025, an estimated $95.1K.
  • Shay Capital first reported a position in Karyopharm Therapeutics in Q4 2024 and held it in 2 quarters.
  • Shay Capital's Karyopharm Therapeutics position peaked at $116K in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.